An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Inclusion Criteria:

• Participant's parent/caregiver/legally authorized representative and participant (ifrequired per local country regulation) capable of giving signed informed consent,which includes compliance with the requirements and restrictions listed in the ICFand in this protocol. Informed assent is to be provided by the participant per localcountry regulation.

• Diagnosis of SLE according to the 2019 European League Against Rheumatism/AmericanCollege of Rheumatology (EULAR/ACR) criteria.for at least 6 months prior to signingthe ICF.

• Participant should meet all of following tuberculosis (TB) criteria:

A. No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit

• Female participants of childbearing potential must have a negative pregnancy test atScreening.

• Female participants of childbearing and non-childbearing potential and maleparticipants must adhere to the contraception methods.

• At screening, negative SARS-CoV-2 RT-PCR or rapid antigen test result and no knownor suspected COVID-19 infection or exposure between screening and randomizationvisits.

Exclusion Criteria:

• Known diagnosis of an IFN-mediated autoinflammatory interferonopathy.

• History of, or current diagnosis of, clinically significant non-SLE-relatedvasculitides.

• In participants aged 11 years and above: history or evidence of suicidal ideation.

• History of any non-SLE disease that has required treatment with oral or parenteralcorticosteroids for more than a total of 2 weeks within the last 24 weeks prior tosigning the ICF.

• Any positive result on Screening for human immunodeficiency virus.

• Active hepatitis B surface antigen OR hepatitis B core antibody (HBcAb), hepatitis Cvirus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any severe case ofHerpes Zoster infection.

• Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completelyresolved within 12 weeks prior to signing the ICF.

• History of severe COVID-19 infection requiring hospitalization, intensive care unitcare, or assisted ventilation or any prior COVID-19 infection with unresolvedsequelae. Any mild/asymptomatic COVID-19 infection (laboratory confirmed orsuspected based on clinical symptoms).

• Prior use of Anifrolumab.

• Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg,rituximab) < 26 weeks prior to ICF signature.

• Blood transfusion or receipt of blood products except albumin within 4 weeks priorto signing the ICF.